Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanism of action of Gaviscon Advance in gastro-oesophageal reflux disease
2010-019072-68Phase 4Completed
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of gaviscon advance in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Guy's and St Thomas' NHS Foundation Trust. Primary endpoint: Number of reflux episodes in 4-hour postprandial period. Started Dec 2010; status: completed.
02
Drugs
gaviscon advance
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2010-019072-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019072-68.